“The continuous efforts by vendors to manufacture contamination-free
vaccines with novel culture media along with strict regulatory checks by
the government are likely to drive market growth in terms of both value
and volume”

The market study covers the present scenario and growth prospects of the
global rabies
treatment marketfor 2017-2021. The report also lists pre-exposure
prophylaxis and post-exposure prophylaxis as the two major
application segments.

Technavio’s sample reports are free of charge and contain multiple
sections of the report including the market size and forecast, drivers,
challenges, trends, and more.

Technavio analysts highlight the following three market drivers that are
contributing to the growth of the global rabies treatment market:

The need for contamination-free vaccines with novel culture media

Growing issue of stray animals in developing economies

Novel routes of administration

The need for contamination-free vaccines with novel culture media

Vaccines currently available for human use are cultured using
formulations containing human or animal components. To eradicate the
risk of contamination of vaccines by BSE agents or human components,
vendors are focusing on the development of novel vaccine production
medias that are free from animal and human components. For instance,
Sanofi is developing an enhanced version of PVRV-NG, which is free from
bovine serum and fetal tissue. This next-generation vaccine contains
inactivated Pitman-Moore strain of rabies virus, which is common to
currently available vaccines like Imovax and Verorab.

“The continuous efforts by vendors to manufacture contamination-free
vaccines with novel culture media along with strict regulatory checks by
the government are likely to drive market growth in terms of both value
and volume,” says Sapna Jha, a lead analyst at Technavio for infectious
and rare diseasesresearch.

Growing issue of stray animals in developing economies

Rabies is a zoonotic disorder that is transmitted through the saliva of
a rabid animal to humans as well as to other animals. The increasing
stray dog population and the absence of effective rabies vaccination
programs in developing economies make these regions the major sources of
rabies worldwide. As per CDC, 90% of all rabies cases and 99% of
rabies-related deaths are due to the exposure to rabid dogs and accounts
for more than 99% deaths due to rabies worldwide. Thus, the demand for
anti-rabies treatment regimen such as cell culture vaccines (CCVs) and
rabies immunoglobulin (RIGs) for post-exposure prophylaxis is high. This
increase in the demand for rabies vaccine for post-exposure prophylaxis,
is likely to drive market growth in terms of both volume and value.

Novel routes of administration

The high cost of CCVs for intramuscular administration has posed a major
challenge for the widespread adoption of these vaccines in developing
countries for pre-exposure and post-exposure prophylaxis against rabies.
To overcome this hurdle, the WHO recommends the intradermal
administration of CCVs for post-exposure prophylaxis of rabies in
countries where rabies is prevalent and intramuscular biological for
rabies is unavailable and unaffordable. The intradermal vaccine requires
only 1-2 doses to complete the full course of post-exposure prophylaxis
and helps reduce the volume used and cost of vaccine by at least 55%-65%
compared with intramuscular vaccines.

“Intradermal vaccines have similar potency as intramuscular vaccines
and provide a safe and immunogenic alternative at a lower cost.
Intradermal vaccines have been introduced in developing countries such
as India, the Philippines, Sri Lanka, and Thailand. Considering the high
prevalence of rabies and the low income of people in these countries,
the introduction of cost-effective alternatives is likely to drive the
market growth,” says Sapna.

Become a Technavio
Insights member and access all three of these reports for a
fraction of their original cost. As a Technavio Insights member, you
will have immediate access to new reports as they’re published in
addition to all 6,000+ existing reports covering segments like oncology,
vaccines, and urology devices. This subscription nets you thousands in
savings, while staying connected to Technavio’s constant transforming
research library, helping you make informed business decisions more
efficiently.

About Technavio

Technaviois a leading global technology research and advisory company. The
company develops over 2000 pieces of research every year, covering more
than 500 technologies across 80 countries. Technavio has about 300
analysts globally who specialize in customized consulting and business
research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
re-sellers, and end-users.

If you are interested in more information, please contact our media team
at media@technavio.com.